Collaborative Engagement on Access to Medicine and SDG3

26 members


The Access to Medicine Index ranks 20 of the world’s largest research-based pharmaceutical companies on the basis of how they manage risks and opportunities related to access to medicine in low- and middle-income countries. The collaborative engagement is a long-term engagement project for tracking the progress of pharmaceutical companies towa

Business case

The Access to Medicine Index measures a range of value drivers within the pharmaceutical business model, including governance, R&D, pricing and compliance. The collaborative engagement covers the 19 listed companies in the 2018 Access to Medicine Index. These companies together account for approximately 60-70% of global pharmaceutical revenues.

Expanding access to medicine will help pharma companies enhance shareholder value in several ways:

  • Unlock growth potential in emerging markets by reaching new populations.
  • Mitigate the risk of unethical conduct.
  • Enhance corporate reputations.
  • Contribute to the creation of healthy societies.

You can read more here and here.

Companies covered in the collaborative engagement: AbbVie Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi-Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly & Co., Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Merck & Co., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Co. Ltd.

Collaboration details

Open To Join
ESG theme
  • Social
Created on